Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, has announced a strategic collaboration with NVIDIA to accelerate the development of its multimodal AI foundation model platform. The partnership aims to advance precision medicine by leveraging Natera’s extensive longitudinal and multi-time point in vivo datasets alongside NVIDIA’s high-performance computing platforms, AI frameworks, and accelerated software libraries. Under the collaboration, Natera will integrate its proprietary machine learning models and one of the largest multimodal oncology datasets in the world with NVIDIA’s technology stack. This includes NVIDIA Parabricks for speeding up bioinformatics workflows, NVIDIA BioNeMo for optimizing large-scale model training, and the NVIDIA NeMo Agent Toolkit for developing multi-agent AI systems tailored for clinical and research applications. Early results show significant improvements in efficiency—average reductions of 75.7% in runtime and 59.2% in cost using Parabricks for genomic analysis, along with a 45.5% increase in training speed through NVIDIA Transformer Engine integration. Natera’s AI-driven solutions have demonstrated strong performance in critical areas of oncology. Its NeoSelect™ algorithm for neoantigen prioritization outperformed 25 existing prediction tools, while NeoPredict™, designed to forecast immunotherapy response, delivered more than a two-fold improvement in hazard ratios compared to tumor mutational burden—the current clinical standard. These capabilities are already attracting interest from pharmaceutical partners, leading to new data collaborations and growth in Natera’s data business. The company’s vision, as stated by co-founder and executive chairman Matthew Rabinowitz, is to build a computational foundation for biological intelligence. “By combining Natera’s AI-ready data with NVIDIA’s compute and software, we can train at unprecedented scale and develop AI systems that interpret biology and reason across diverse data types—marking a major leap in personalized diagnostics and therapeutic insights.” NVIDIA’s Rory Kelleher, senior director of global business development for life sciences, emphasized that AI is transforming precision medicine by improving the speed and accuracy of biological discovery. “With NVIDIA’s accelerated computing and advanced AI frameworks, Natera’s unique data and platform are helping unlock better diagnostics, deeper biological understanding, and more personalized treatments.” Natera’s global testing and research networks generate vast amounts of data annually, providing the scale needed to train increasingly sophisticated AI models. The collaboration with NVIDIA is expected to drive innovation across precision oncology, organ health, and beyond, supporting earlier, more targeted interventions and improved patient outcomes. Natera operates multiple CLIA- and CAP-accredited laboratories in the U.S., including facilities in Austin, San Carlos, and Boulder, and is supported by over 350 peer-reviewed publications. The company continues to advance its mission of making personalized genetic testing a standard of care.